# INTERNATIONAL BIOTECHNOLOGY TRUST PLC

> Institutional holdings reported to the SEC as of Q3 2023 on Form 13F. CIK 942257. Source: https://holderbook.com/funds/942257-international-biotechnology-trust-plc/

- Reported value: $296.8M
- Positions: 65
- Weight of the ten largest: 47.8%
- Filed: 2023-11-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| AMGEN INC | [AMGN](https://holderbook.com/stocks/AMGN/) | $21.3M | 79,246 | 7.2% | 20 |
| INCYTE CORP | [INCY](https://holderbook.com/stocks/INCY/) | $20.7M | 358,454 | 7.0% | 20 |
| GILEAD SCIENCES INC | [GILD](https://holderbook.com/stocks/GILD/) | $17.5M | 233,584 | 5.9% | 20 |
| INTRA-CELLULAR THERAPIES INC | [ITCI](https://holderbook.com/stocks/ITCI/) | $16.5M | 317,856 | 5.6% | 15 |
| BIOMARIN PHARMACEUTICAL INC | [BMRN](https://holderbook.com/stocks/BMRN/) | $13.6M | 153,656 | 4.6% | 20 |
| SUPERNUS PHARMACEUTICALS | [SUPN](https://holderbook.com/stocks/SUPN/) | $11.8M | 426,500 | 4.0% | 10 |
| VERA THERAPEUTICS INC | [VERA](https://holderbook.com/stocks/VERA/) | $10.4M | 758,355 | 3.5% | 8 |
| BIOGEN INC | [BIIB](https://holderbook.com/stocks/BIIB/) | $10.3M | 40,200 | 3.5% | 6 |
| HARMONY BIOSCIENCES HLDGS IN | [HRMY](https://holderbook.com/stocks/HRMY/) | $10.3M | 314,500 | 3.5% | 10 |
| MIRATI THERAPEUTICS INC | [MRTX](https://holderbook.com/stocks/MRTX/) | $9.4M | 216,000 | 3.2% | 19 |
| ULTRAGENYX PHARMACEUTICAL IN | [RARE](https://holderbook.com/stocks/RARE/) | $8.9M | 250,052 | 3.0% | 11 |
| UNIQURE NV | [QURE](https://holderbook.com/stocks/QURE/) | $8.3M | 1,241,500 | 2.8% | 18 |
| AURINIA PHARMACEUTICALS INC | [AUPH](https://holderbook.com/stocks/AUPH/) | $8.1M | 1,040,530 | 2.7% | 13 |
| UNITED THERAPEUTICS CORP DEL | [UTHR](https://holderbook.com/stocks/UTHR/) | $7.7M | 33,959 | 2.6% | 7 |
| VERTEX PHARMACEUTICALS INC | [VRTX](https://holderbook.com/stocks/VRTX/) | $7.3M | 21,000 | 2.5% | 3 |
| REGENERON PHARMACEUTICALS | [REGN](https://holderbook.com/stocks/REGN/) | $7.3M | 8,847 | 2.5% | 14 |
| ILLUMINA INC | [ILMN](https://holderbook.com/stocks/ILMN/) | $6.9M | 50,500 | 2.3% | 9 |
| ALNYLAM PHARMACEUTICALS INC | [ALNY](https://holderbook.com/stocks/ALNY/) | $6.5M | 36,800 | 2.2% | 20 |
| AMYLYX PHARMACEUTICALS INC | [AMLX](https://holderbook.com/stocks/AMLX/) | $5.4M | 295,000 | 1.8% | 2 |
| KRYSTAL BIOTECH INC | [KRYS](https://holderbook.com/stocks/KRYS/) | $5.3M | 46,092 | 1.8% | 8 |
| KARUNA THERAPEUTICS INC | [KRTX](https://holderbook.com/stocks/KRTX/) | $5.2M | 30,500 | 1.7% | 3 |
| AXSOME THERAPEUTICS INC | [AXSM](https://holderbook.com/stocks/AXSM/) | $4.1M | 58,300 | 1.4% | 2 |
| ERASCA INC | [ERAS](https://holderbook.com/stocks/ERAS/) | $3.8M | 1,926,000 | 1.3% | 3 |
| ACADIA PHARMACEUTICALS INC | [ACAD](https://holderbook.com/stocks/ACAD/) | $3.7M | 179,702 | 1.3% | 4 |
| REVANCE THERAPEUTICS INC | [RVNC](https://holderbook.com/stocks/RVNC/) | $3.3M | 288,726 | 1.1% | 5 |
| NEUROCRINE BIOSCIENCES INC | [NBIX](https://holderbook.com/stocks/NBIX/) | $3.2M | 28,877 | 1.1% | 2 |
| SAREPTA THERAPEUTICS INC | [SRPT](https://holderbook.com/stocks/SRPT/) | $3.2M | 26,700 | 1.1% | 2 |
| ROCKET PHARMACEUTICALS INC | [RCKT](https://holderbook.com/stocks/RCKT/) | $3.2M | 156,000 | 1.1% | 9 |
| DENALI THERAPEUTICS INC | [DNLI](https://holderbook.com/stocks/DNLI/) | $3.2M | 154,000 | 1.1% | 8 |
| ASTRAZENECA PLC | [AZN](https://holderbook.com/stocks/AZN/) | $3.1M | 46,500 | 1.1% | 1 |
| XENON PHARMACEUTICALS INC | [XENE](https://holderbook.com/stocks/XENE/) | $3.1M | 91,500 | 1.1% | 10 |
| CRISPR THERAPEUTICS AG | [CRSP](https://holderbook.com/stocks/CRSP/) | $2.9M | 63,000 | 1.0% | 1 |
| MADRIGAL PHARMACEUTICALS INC | [MDGL](https://holderbook.com/stocks/MDGL/) | $2.7M | 18,300 | 0.9% | 2 |
| LEGEND BIOTECH CORP | [LEGN](https://holderbook.com/stocks/LEGN/) | $2.6M | 38,000 | 0.9% | 9 |
| HALOZYME THERAPEUTICS INC | [HALO](https://holderbook.com/stocks/HALO/) | $2.4M | 62,200 | 0.8% | 3 |
| MARINUS PHARMACEUTICALS INC | [MRNS](https://holderbook.com/stocks/MRNS/) | $2.3M | 290,000 | 0.8% | 2 |
| BEONE MEDICINES LTD | [ONC](https://holderbook.com/stocks/ONC/) | $2.3M | 12,700 | 0.8% | 8 |
| JAZZ PHARMACEUTICALS PLC | [JAZZ](https://holderbook.com/stocks/JAZZ/) | $2.2M | 17,200 | 0.7% | 10 |
| MIRUM PHARMACEUTICALS INC | [MIRM](https://holderbook.com/stocks/MIRM/) | $2.1M | 67,500 | 0.7% | 5 |
| IOVANCE BIOTHERAPEUTICS INC | [IOVA](https://holderbook.com/stocks/IOVA/) | $2.0M | 445,000 | 0.7% | 13 |
| IONIS PHARMACEUTICALS INC | [IONS](https://holderbook.com/stocks/IONS/) | $1.9M | 43,000 | 0.7% | 3 |
| ZAI LAB LTD | [ZLAB](https://holderbook.com/stocks/ZLAB/) | $1.9M | 78,958 | 0.6% | 10 |
| GENMAB A/S | [GMAB](https://holderbook.com/stocks/GMAB/) | $1.6M | 44,300 | 0.5% | 1 |
| CELLDEX THERAPEUTICS INC NEW | [CLDX](https://holderbook.com/stocks/CLDX/) | $1.3M | 48,099 | 0.4% | 2 |
| COGENT BIOSCIENCES INC | [COGT](https://holderbook.com/stocks/COGT/) | $1.3M | 135,000 | 0.4% | 1 |
| DYNE THERAPEUTICS INC | [DYN](https://holderbook.com/stocks/DYN/) | $1.2M | 137,751 | 0.4% | 11 |
| NOVOCURE LTD | [NVCR](https://holderbook.com/stocks/NVCR/) | $1.2M | 74,000 | 0.4% | 6 |
| AMICUS THERAPEUTICS INC | [FOLD](https://holderbook.com/stocks/FOLD/) | $1.1M | 90,000 | 0.4% | 1 |
| CYTOKINETICS INC | [CYTK](https://holderbook.com/stocks/CYTK/) | $1.1M | 37,000 | 0.4% | 2 |
| GUARDANT HEALTH INC | [GH](https://holderbook.com/stocks/GH/) | $1.1M | 36,500 | 0.4% | 10 |
| INSMED INC | [INSM](https://holderbook.com/stocks/INSM/) | $1.0M | 40,100 | 0.3% | 19 |
| BLUEPRINT MEDICINES CORP | [BPMC](https://holderbook.com/stocks/BPMC/) | $1.0M | 20,000 | 0.3% | 1 |
| AKERO THERAPEUTICS INC | [AKRO](https://holderbook.com/stocks/AKRO/) | $935.2K | 18,489 | 0.3% | 2 |
| KEZAR LIFE SCIENCES INC | [KZR](https://holderbook.com/stocks/KZR/) | $830.5K | 703,825 | 0.3% | 1 |
| INTELLIA THERAPEUTICS INC | [NTLA](https://holderbook.com/stocks/NTLA/) | $757.9K | 24,000 | 0.3% | 8 |
| PROTHENA CORP PLC | [PRTA](https://holderbook.com/stocks/PRTA/) | $722.9K | 15,000 | 0.2% | 1 |
| AGIOS PHARMACEUTICALS INC | [AGIO](https://holderbook.com/stocks/AGIO/) | $593.5K | 24,000 | 0.2% | 2 |
| BEAM THERAPEUTICS INC | [BEAM](https://holderbook.com/stocks/BEAM/) | $564.7K | 23,500 | 0.2% | 6 |
| VENTYX BIOSCIENCES INC | [VTYX](https://holderbook.com/stocks/VTYX/) | $520.6K | 15,000 | 0.2% | 3 |
| VIR BIOTECHNOLOGY INC | [VIR](https://holderbook.com/stocks/VIR/) | $439.9K | 47,000 | 0.1% | 1 |
| NOVABRIDGE BIOSCIENCES | [NBP](https://holderbook.com/stocks/NBP/) | $409.9K | 310,499 | 0.1% | 11 |
| PTC THERAPEUTICS INC | [PTCT](https://holderbook.com/stocks/PTCT/) | $380.6K | 17,000 | 0.1% | 19 |
| ARVINAS INC | [ARVN](https://holderbook.com/stocks/ARVN/) | $333.5K | 17,000 | 0.1% | 5 |
| PROTAGONIST THERAPEUTICS INC | [PTGX](https://holderbook.com/stocks/PTGX/) | $331.9K | 19,900 | 0.1% | 2 |
| RELMADA THERAPEUTICS INC | [RLMD](https://holderbook.com/stocks/RLMD/) | $30.0K | 10,000 | 0.0% | 9 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q3 2023 | -8.2% | -3.6% | -4.6% | 98% |
| Q2 2023 | +1.2% | +8.3% | -7.1% | 100% |
| Q1 2023 | +1.0% | +7.0% | -6.1% | 88% |
| Q4 2022 | +5.0% | +7.1% | -2.1% | 91% |
| Q3 2022 | -2.6% | -5.3% | +2.7% | 148% |
| Q2 2022 | -9.9% | -16.5% | +6.5% | 76% |
| Q1 2022 | -8.5% | -4.9% | -3.6% | 102% |
| Q4 2021 | -3.0% | +10.7% | -13.7% | 92% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q3 2023 | $296.8M | 65 |
| Q2 2023 | $328.5M | 61 |
| Q1 2023 | $358.4M | 64 |
| Q4 2022 | $323.8M | 63 |
| Q3 2022 | $311.9M | 66 |
| Q2 2022 | $9.6M | 78 |
| Q1 2022 | $443.4M | 70 |
| Q4 2021 | $448.9M | 73 |
| Q3 2021 | $414.6M | 68 |
| Q2 2021 | $378.8M | 66 |
| Q1 2021 | $378.1M | 56 |
| Q4 2020 | $366.1M | 52 |